Embecta (EMBC) Competitors $11.91 +0.01 (+0.08%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$12.38 +0.47 (+3.95%) As of 04:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EMBC vs. PRCT, NVST, TMDX, LIVN, ENOV, NVCR, LMAT, CNMD, WRBY, and CDREShould you be buying Embecta stock or one of its competitors? The main competitors of Embecta include PROCEPT BioRobotics (PRCT), Envista (NVST), TransMedics Group (TMDX), LivaNova (LIVN), Enovis (ENOV), NovoCure (NVCR), LeMaitre Vascular (LMAT), CONMED (CNMD), Warby Parker (WRBY), and Cadre (CDRE). These companies are all part of the "medical equipment" industry. Embecta vs. PROCEPT BioRobotics Envista TransMedics Group LivaNova Enovis NovoCure LeMaitre Vascular CONMED Warby Parker Cadre PROCEPT BioRobotics (NASDAQ:PRCT) and Embecta (NASDAQ:EMBC) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, community ranking, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment. Is PRCT or EMBC more profitable? Embecta has a net margin of 5.25% compared to PROCEPT BioRobotics' net margin of -50.07%. Embecta's return on equity of -19.22% beat PROCEPT BioRobotics' return on equity.Company Net Margins Return on Equity Return on Assets PROCEPT BioRobotics-50.07% -38.57% -26.06% Embecta 5.25%-19.22%11.92% Does the MarketBeat Community favor PRCT or EMBC? PROCEPT BioRobotics received 40 more outperform votes than Embecta when rated by MarketBeat users. Likewise, 69.49% of users gave PROCEPT BioRobotics an outperform vote while only 5.56% of users gave Embecta an outperform vote. CompanyUnderperformOutperformPROCEPT BioRoboticsOutperform Votes4169.49% Underperform Votes1830.51% EmbectaOutperform Votes15.56%Underperform Votes1794.44% Which has more risk and volatility, PRCT or EMBC? PROCEPT BioRobotics has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Embecta has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Do analysts recommend PRCT or EMBC? PROCEPT BioRobotics currently has a consensus price target of $91.43, suggesting a potential upside of 72.77%. Embecta has a consensus price target of $20.33, suggesting a potential upside of 70.72%. Given PROCEPT BioRobotics' stronger consensus rating and higher probable upside, equities analysts plainly believe PROCEPT BioRobotics is more favorable than Embecta.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PROCEPT BioRobotics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Embecta 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has higher valuation and earnings, PRCT or EMBC? Embecta has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPROCEPT BioRobotics$224.50M12.92-$105.90M-$1.76-30.07Embecta$1.11B0.63$78.30M$1.0011.91 Does the media favor PRCT or EMBC? In the previous week, PROCEPT BioRobotics had 6 more articles in the media than Embecta. MarketBeat recorded 16 mentions for PROCEPT BioRobotics and 10 mentions for Embecta. PROCEPT BioRobotics' average media sentiment score of 1.01 beat Embecta's score of 0.99 indicating that PROCEPT BioRobotics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PROCEPT BioRobotics 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Embecta 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in PRCT or EMBC? 89.5% of PROCEPT BioRobotics shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 17.4% of PROCEPT BioRobotics shares are held by insiders. Comparatively, 0.4% of Embecta shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryPROCEPT BioRobotics and Embecta tied by winning 9 of the 18 factors compared between the two stocks. Remove Ads Get Embecta News Delivered to You Automatically Sign up to receive the latest news and ratings for EMBC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EMBC vs. The Competition Export to ExcelMetricEmbectaSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$692.38M$4.07B$5.33B$7.57BDividend Yield4.88%39.49%5.11%4.32%P/E Ratio11.9127.6321.6617.82Price / Sales0.6350.21373.3994.61Price / Cash4.3251.0838.1534.64Price / Book-0.905.826.474.00Net Income$78.30M$67.09M$3.20B$247.23M7 Day Performance-5.85%-0.17%2.86%1.45%1 Month Performance-9.43%-3.20%-8.56%-6.24%1 Year Performance15.07%14.84%10.58%0.60% Embecta Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EMBCEmbecta4.5295 of 5 stars$11.91+0.1%$20.33+70.7%+12.5%$692.38M$1.11B11.911,900PRCTPROCEPT BioRobotics2.3992 of 5 stars$50.83-0.8%$94.29+85.5%+4.6%$2.79B$224.50M-26.07430Positive NewsGap DownHigh Trading VolumeNVSTEnvista4.3811 of 5 stars$15.27-1.4%$20.18+32.2%-21.0%$2.63B$2.51B-2.3512,700Analyst ForecastAnalyst RevisionNews CoveragePositive NewsGap DownTMDXTransMedics Group2.7684 of 5 stars$69.15+2.2%$122.70+77.4%-5.1%$2.33B$441.54M73.56210LIVNLivaNova3.561 of 5 stars$35.40-1.5%$61.17+72.8%-34.8%$1.92B$1.25B84.292,900Positive NewsHigh Trading VolumeENOVEnovis2.2227 of 5 stars$32.41-0.4%$58.50+80.5%-44.7%$1.85B$2.11B-14.806,800NVCRNovoCure3.335 of 5 stars$16.61+0.7%$35.80+115.5%+29.4%$1.83B$605.22M-11.861,320LMATLeMaitre Vascular3.0974 of 5 stars$79.39-0.5%$95.25+20.0%+31.3%$1.79B$219.86M43.38490Positive NewsHigh Trading VolumeCNMDCONMED4.7109 of 5 stars$55.34-1.6%$77.20+39.5%-35.5%$1.71B$1.31B13.054,100WRBYWarby Parker3.3236 of 5 stars$15.43-2.2%$23.43+51.8%+13.5%$1.60B$771.32M-57.153,491Analyst ForecastPositive NewsGap DownCDRECadre3.4227 of 5 stars$28.30+0.5%$37.00+30.7%-7.8%$1.15B$567.56M34.102,240 Remove Ads Related Companies and Tools Related Companies PRCT Alternatives NVST Alternatives TMDX Alternatives LIVN Alternatives ENOV Alternatives NVCR Alternatives LMAT Alternatives CNMD Alternatives WRBY Alternatives CDRE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EMBC) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredRadical shift coming to the stock market (read this ASAP)This is an urgent warning for all American investors … In a matter of days, we could see a radical shift in...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Embecta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EMBC Stock Free EMBC Stock Alerts